Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

Item

http://www.wikidata.org/entity/Q36023889

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@ast

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@en

type

Item

label

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@ast

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@en

prefLabel

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@ast

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@en

P1476

Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

@en

P2093

Alison M Ivey

http://www.w3.org/2001/XMLSchema#string

Jose G Trevino

http://www.w3.org/2001/XMLSchema#string

Neelam V Desai

http://www.w3.org/2001/XMLSchema#string

Robert A Zlotecki

http://www.w3.org/2001/XMLSchema#string

Sarunas Sliesoraitis

http://www.w3.org/2001/XMLSchema#string

Steven J Hughes

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.

Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.

A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin.

Gemcitabine-radiotherapy in patients with locally advanced pancreatic cancer.

P304

1224-1239

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1002/CAM4.444

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas J George

P5008

ScienceSource

P577

2015-03-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273464376

http://www.w3.org/2001/XMLSchema#string

P698

25766842

http://www.w3.org/2001/XMLSchema#string

P921

pancreatic cancer

P932

4559034

http://www.w3.org/2001/XMLSchema#string